

12/14/01
JC914.LS_PTO

Please type a '+' sign (+) inside this box → +

12-18-01

A/Box 5 Sec

PTO/SB/05 (03-01)

OMB 0651-0002

Approved for use through 10/31/2002 U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**
(Only for new nonprovisional applications under 37 CFR 1.53 (b))

Attorney Docket No. LEX-0282-USA
First Inventor Walke, et al.
Title Novel Human Alpha Macroglobulin Family Proteins and Polynucleotides Encoding the Same

Express Mail Label No. EV 017075762 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application

1. Fee Transmittal Form (e.g., PTO/SB/17)

2. Applicant claims small entity status.
See 37 CFR 1.27.

3. Specification [Total Pages 33] 33

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed Sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Description of the Invention(s) (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

4. Drawing(s)/35 U.S.C.113) [Total Sheets 2]

5. Oath or Declaration [Total Pages 2]

a. Unexecuted

b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)

i. DELETION OF INVENTOR(S)
signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Prior application information: Examiner _____ Group Art Unit: _____
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	 (Insert Customer No. or Attach bar code label here)		or <input type="checkbox"/> Correspondence address below 2421		
Name	PATENT TRADEMARK OFFICE				
Address					
City	State	Zip			
Country	Telephone	Fax			

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866
Signature	Lance K. Ishimoto by David W. Hister		David W. HISTER Reg. No. 4,071
Date	December 14, 2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL

for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)

Complete if Known

Application Number	Not Yet Assigned
Filing Date	December 14, 2001
First Named Inventor	Walke et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	LEX-0282-USA

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account Number 50-0892
 Deposit Account Name

Charge Any Additional Fee Required
 Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status
 See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205		65	Surcharge - late filing fee or oath	<input type="checkbox"/>
127	50	227		25	Surcharge - late provisional filing fee or cover sheet	<input type="checkbox"/>
139	130	139		130	Non-English specification	<input type="checkbox"/>
147	2,520	147	2,520	2,520	For filing a request for ex parte reexamination	<input type="checkbox"/>
112	920*	112	920*	920*	Requesting publication of SIR prior to Examiner action	<input type="checkbox"/>
113	1,840*	113	1,840*	1,840*	Requesting publication of SIR after	<input type="checkbox"/>
115	110	215		55	Extension for reply within first month	<input type="checkbox"/>
116	400	216		200	Extension for reply within second month	<input type="checkbox"/>
117	920	217		460	Extension for reply within third month	<input type="checkbox"/>
118	1,440	218		720	Extension for reply within fourth month	<input type="checkbox"/>
128	1,860	228		980	Extension for reply within fifth month	<input type="checkbox"/>
119	320	219		160	Notice of Appeal	<input type="checkbox"/>
120	320	220		160	Filing a brief in support of an appeal	<input type="checkbox"/>
121	280	221		140	Request for oral hearing	<input type="checkbox"/>
138	1,510	138		1,510	Petition to institute a public use proceeding	<input type="checkbox"/>
140	110	240		55	Petition to revive - unavoidable	<input type="checkbox"/>
141	1,280	241		640	Petition to revive - unintentional	<input type="checkbox"/>
142	1,280	242		640	Utility issue fee (or reissue)	<input type="checkbox"/>
143	460	243		230	Design issue fee	<input type="checkbox"/>
144	620	244		310	Plant issue fee	<input type="checkbox"/>
122	130	122		130	Petitions to the Commissioner	<input type="checkbox"/>
123	50	123		50	Processing fee under 37 CFR 1.17(q)	<input type="checkbox"/>
126	180	128		180	Submission of Information Disclosure Stmt	<input type="checkbox"/>
581	40	581		40	Recording each patent assignment per property (times number of properties)	<input type="checkbox"/>
146	740	248		370	Filing a submission after final rejection (37 CFR 1.129(a))	<input type="checkbox"/>
149	740	249		370	For each additional invention to be examined (37 CFR 1.129(b))	<input type="checkbox"/>
179	740	279		370	Request for Continued Examination (RCE)	<input type="checkbox"/>
169	900	169		900	Request for expedited examination of a design application	<input type="checkbox"/>
Other fee (specify) _____						
SUBTOTAL (3) (\$)						

*or number previously paid, if greater; For Reissues, see above

SUBMITTED BY Basic Filing Fee Paid

(\$)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866	Telephone	281-863-3333
Signature	Lance K. Ishimoto by David W. Higbee	DAVID W. HIGBEE REG. NO. 44,071		Date	December 14, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)		First Named Inventor	Walke, et al.
Title	Novel Human Alpha Macroglobulin Family Proteins and Polynucleotides Encoding the		
Atty Docket Number	LEX-0282-USA		

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

12-14-01

Date

Lance K. Ishimoto by David W. Webster
Signature DAVID W. WEBSTER
REG. NO. 44,071

Lance K. Ishimoto Reg No 41,866
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(ii)).**

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Walke et al.

U.S. Ser. No.: To be assigned Attorney Docket No.: LEX-0282-USA

Filing Date: December 14, 2001

For: Novel Human Alpha Macroglobulin
Family Proteins and Polynucleotides
Encoding the Same

VERIFIED STATEMENT

Box Patent Application
Commission for Patents
Washington, D.C. 20231

Sir:

I, DRENDA D. THOMAS, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.

2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,


Drenda D. Thomas

December 14, 2001
Date